Ito Süffert Soraya Camargo, Mantese Carlos Eduardo Aliatti, Meira Felipe Rodrigo de Castro, Trindade Katia Flavia Rosso de Oliveira, Etges Ana Paula Beck da Silva, Vargas Alves Rafael José, Bica Claudia Giuliano
Graduate Program of Pathology, Federal University of Health Sciences of Porto Alegre (UFCSPA), Porto Alegre, Brazil.
Hospital Sírio Libanês, São Paulo, Brazil.
Am J Hosp Palliat Care. 2025 Sep;42(9):932-961. doi: 10.1177/10499091241285890. Epub 2024 Sep 23.
ObjectivesIdentify the costs of an oncology patient at the end of life.MethodsA systematic literature review was conducted by screening Embase, PubMed and Lilacs databases, including all studies evaluating end-of-life care costs for cancer patients up to March 2024. The review writing followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The quality of the included studies was assessed using the Drummond checklist. The protocol is available at PROSPERO CRD42023403186.ResultsA total of 733 studies were retrieved, and 43 were considered eligible. Among the studies analyzed, 41,86% included all types of neoplasms, 18.60% of lung neoplasm, All articles performed direct cost analysis, and 9.30% also performed indirect cost analysis. No study evaluated intangible costs, and most presented the macrocosting methodology from the payer's perspective. The articles included in this review presented significant heterogeneity related to populations, diagnoses, periods considered for evaluation of end-of-life care, and cost analyses. Most of the studies were from a payer perspective (74,41%) and based on macrocosting methodologies (81,39%), which limit the use of the information to evaluate variabilities in the consumption of resources.ConclusionsConsidering the complexity of end-of-life care and the need for consistent data on costs in this period, new studies, mainly in low- and middle-income countries with approaches to indirect and intangible costs, with a societal perspective, are important for public policies of health in accordance with the trend of transforming value-based care, allowing the health care system to create more value for patients and their families.
目的
确定肿瘤患者临终时的费用。
方法
通过筛选Embase、PubMed和Lilacs数据库进行系统文献综述,纳入截至2024年3月所有评估癌症患者临终护理费用的研究。综述撰写遵循系统评价和Meta分析的首选报告项目指南。使用Drummond清单评估纳入研究的质量。该方案可在PROSPERO CRD42023403186获取。
结果
共检索到733项研究,43项被认为符合条件。在分析的研究中,41.86%包括所有类型的肿瘤,18.60%为肺癌。所有文章均进行了直接成本分析,9.30%还进行了间接成本分析。没有研究评估无形成本,大多数从支付方角度介绍宏观成本核算方法。本综述纳入的文章在人群、诊断、评估临终护理的时间段以及成本分析方面存在显著异质性。大多数研究从支付方角度(74.41%)且基于宏观成本核算方法(81.39%),这限制了利用这些信息评估资源消耗的变异性。
结论
考虑到临终护理的复杂性以及这一时期对成本一致数据的需求,新的研究,主要是在低收入和中等收入国家开展的、采用间接和无形成本方法且从社会角度进行的研究,对于符合基于价值的护理转变趋势的卫生公共政策很重要,能使医疗保健系统为患者及其家庭创造更多价值。